TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16118673

Group type: COMPARATOR
Intervention: IFN-alpha monotherapy (13 patients) at 9 million units 3 times weekly for 24 weeks
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Combination therapy (14 patients) with IFN-alpha at 9 million units 3 times weekly for 24 weeks plus lamivudine 100 mg/day for 1 year
Number of subjects: 27
Study: 11808827

Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Alfentanil and Ketamine
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 10519562

Group type: EXPERIMENTAL
Intervention: Fibromyalgia patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Maintenance chiropractic care patients
Number of subjects: 0
Study: 7742706

Group type: EXPERIMENTAL
Intervention: O2‐O3 therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: HBO therapy
Number of subjects: 30
Study: 1675576

Group type: EXPERIMENTAL
Intervention: Betaxolol 10 mg (B10)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Betaxolol 40 mg (B40)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Betaxolol 80 mg (B80)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg (A50)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Atenolol 200 mg (A200)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 6
Study: 6825584

Group type: EXPERIMENTAL
Intervention: Levothyroxine
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Prednisone (massive single dose and then alternating daily)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Retrobulbar X‐radiation
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Lymphokinetic drug (Venalot‐Depot)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Combination of treatments
Number of subjects: 148
Study: 30100106

Group type: EXPERIMENTAL
Intervention: 0.04 g hydrolyzed casein protein×kg ffm-1×2 h-1
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 0.10 g hydrolyzed casein protein×kg ffm-1×2 h-1
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 0.30 g hydrolyzed casein protein×kg ffm-1×2 h-1
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Anabolic capacity COPD
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Anabolic capacity healthy
Number of subjects: 22
Study: 29510651

Group type: EXPERIMENTAL
Intervention: Group Therapy (GT)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Individual Therapy (IT)
Number of subjects: 65

Group type: COMPARATOR
Intervention: No Therapy (NT)
Number of subjects: 65
Study: 26964798

Group type: EXPERIMENTAL
Intervention: Low-level infrared laser (LLIL; 810 nm)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Low-level red laser (LLRL; 660 nm, 200 mW, 15 s, 12 J/cm(2))
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo (no energy output)
Number of subjects: 66
Study: 25143497

Group type: EXPERIMENTAL
Intervention: Transtrapezial approach
Number of subjects: 28

Group type: COMPARATOR
Intervention: Standard volar approach
Number of subjects: 28
Study: 22379625

Group type: EXPERIMENTAL
Intervention: Specialist first-episode treatment plus specialist early intervention for borderline personality
Number of subjects: 16

Group type: COMPARATOR
Intervention: Specialist first-episode treatment alone
Number of subjects: 16
Study: 19967594

Group type: EXPERIMENTAL
Intervention: Walking (45-50% heart rate reserve)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Running (80-85% heart rate reserve)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Passive control
Number of subjects: 18
Study: 18727459

Group type: EXPERIMENTAL
Intervention: High monounsaturated fatty acid diabetes-specific supplement (49.95% calories from fats)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Diabetes-specific supplement (34% calories from fats)
Number of subjects: 30
Study: 15504423

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg QD
Number of subjects: 282

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 282
Study: 12794786

Group type: EXPERIMENTAL
Intervention: Hip school led by physical therapists (T group)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Control group (C group)
Number of subjects: 145
Study: 10595601

Group type: EXPERIMENTAL
Intervention: Hydrocortisone administration
Number of subjects: 16
Study: 8740033

Group type: EXPERIMENTAL
Intervention: Lumboscopy (retroperitoneal laparoscopy)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Laparoscopy (transperitoneal laparoscopy)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lumboscopy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Laparoscopy
Number of subjects: 20
Study: 1888694

Group type: EXPERIMENTAL
Intervention: Amiloride
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 7163723

Group type: EXPERIMENTAL
Intervention: Flurazepam (30 mg, nightly for 2 weeks)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (nightly for 2 weeks)
Number of subjects: 16
Study: 31877311

Group type: EXPERIMENTAL
Intervention: 20 sessions of anodal transcranial direct current stimulation (TDCS) over the left dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: 20 sessions of anodal TDCS with working memory training
Number of subjects: 123

Group type: COMPARATOR
Intervention: 20 sessions of sham stimulation
Number of subjects: 123

Group type: COMPARATOR
Intervention: 20 sessions of sham stimulation with working memory training
Number of subjects: 123
Study: 30696255

Group type: EXPERIMENTAL
Intervention: Nimesulide 100 mg tablet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Celecoxib (CXB) as internal standard
Number of subjects: 0
Study: 27406397

Group type: EXPERIMENTAL
Intervention: Chest compressions with music
Number of subjects: 77

Group type: COMPARATOR
Intervention: No music (control group)
Number of subjects: 77
Study: 26511848

Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine (ASAQ)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Adverse events for ASAQ
Number of subjects: 262

Group type: COMPARATOR
Intervention: Adverse events for AL
Number of subjects: 262
Study: 23398716

Group type: EXPERIMENTAL
Intervention: 3D conformal treatment planning
Number of subjects: 10

Group type: COMPARATOR
Intervention: AP-PA technique
Number of subjects: 10

Group type: COMPARATOR
Intervention: PA technique
Number of subjects: 10
Study: 20952427

Group type: EXPERIMENTAL
Intervention: Clonidine 2 µg kg⁻¹ in bupivacaine 0.2%
Number of subjects: 50

Group type: COMPARATOR
Intervention: Morphine 30 µg kg⁻¹ in bupivacaine 0.2%
Number of subjects: 50
Study: 19192106

Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Baseline HbA(1c)
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Hypertension history
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Metabolic syndrome
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Self-reported use of ED medications
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Complete ED
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Mild or moderate ED
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Sought medical help for ED
Number of subjects: 373
Study: 17374742

Group type: EXPERIMENTAL
Intervention: Intensified maintenance chemotherapy (n = 89)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Observation (n = 86)
Number of subjects: 175
Study: 15125746

Group type: EXPERIMENTAL
Intervention: Gemcitabine with radiotherapy (300 mg/m2/week)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 6

Group type: COMPARATOR
Intervention: Excision followed by radiotherapy
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Gemcitabine with radiotherapy
Number of subjects: 6
Study: 12397466

Group type: EXPERIMENTAL
Intervention: Quadramet (samarium‐153 EDTMP) at an average dose of 740 MBq in tracer studies and up to 50 GBq in therapy infusions.
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Quadramet (samarium‐153 EDTMP) at an average dose of 740 MBq in tracer studies.
Number of subjects: 42
Study: 9817174

Group type: EXPERIMENTAL
Intervention: Gravity-assisted positioning head downward tip (Episode A)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Reverse order positioning (Episode B)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Sitting position during physiotherapy
Number of subjects: 21
Study: 7661492

Group type: EXPERIMENTAL
Intervention: Combination therapy (2.5 g of colestipol plus 2.5 g of psyllium)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Colestipol alone (5 g)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Psyllium alone (5 g)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo (5 g cellulose)
Number of subjects: 121
Study: 2034085

Group type: EXPERIMENTAL
Intervention: Combined therapy using large field radiotherapy (total irradiation of 20 Gy, daily fractionation of 4 Gy) and induced hyperglycemia (22‐23 mmol/l)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Induced hyperglycemia before radiotherapy sessions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Induced hyperglycemia after discontinuation of radiotherapy sessions
Number of subjects: 0
Study: 7034431

Group type: EXPERIMENTAL
Intervention: metronidazole-fosfomycin
Number of subjects: 58

Group type: COMPARATOR
Intervention: metronidazole-cephalothin
Number of subjects: 58
Study: 31658148

Group type: EXPERIMENTAL
Intervention: Prolonged dual antiplatelet therapy (DAPT) (>12 months)
Number of subjects: 5
Study: 30955096

Group type: EXPERIMENTAL
Intervention: Piezocision-assisted orthodontic treatment
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional orthodontic treatment
Number of subjects: 24
Study: 28644196

Group type: EXPERIMENTAL
Intervention: Cebranopadol 200 μg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cebranopadol 400 μg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cebranopadol 600 μg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tapentadol 200 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cebranopadol (all doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cebranopadol (target doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cebranopadol (maintenance phase)
Number of subjects: 0
Study: 23975362

Group type: EXPERIMENTAL
Intervention: Multidisciplinary program, n=108
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Aerobic exercise program, n=47
Number of subjects: 203

Group type: COMPARATOR
Intervention: Usual care, n=48
Number of subjects: 203
Study: 25775881

Group type: EXPERIMENTAL
Intervention: Low-concentration iodinated contrast medium (Iodixanol, 270 mg I/ml) with low tube voltage (80 kV)
Number of subjects: 60

Group type: COMPARATOR
Intervention: High-concentration iodinated contrast medium (Iodixanol, 320 mg I/ml) with standard tube voltage (120 kV)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low-concentration iodinated contrast medium (Iodixanol, 270 mg I/ml)
Number of subjects: 60

Group type: COMPARATOR
Intervention: High-concentration iodinated contrast medium (Iodixanol, 320 mg I/ml)
Number of subjects: 60
Study: 23069363

Group type: EXPERIMENTAL
Intervention: Pedometer-based Green Prescription
Number of subjects: 330

Group type: COMPARATOR
Intervention: Time-based Green Prescription
Number of subjects: 330
Study: 19930003

Group type: EXPERIMENTAL
Intervention: Cinnamon supplementation
Number of subjects: 311
Study: 17323788

Group type: EXPERIMENTAL
Intervention: Ibuprofen sodium dihydrate (256 mg sodium salt, equivalent to 200 mg ibuprofen)
Number of subjects: 396

Group type: COMPARATOR
Intervention: Ibuprofen acid (200 mg ibuprofen)
Number of subjects: 396
Study: 15143880

Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant chemotherapy with biweekly administration of 1000 mg/m2 gemcitabine
Number of subjects: 21

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 21
Study: 11197282

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Esomeprazole 10 mg
Number of subjects: 318

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Esomeprazole (all doses)
Number of subjects: 318
Study: 9537489

Group type: EXPERIMENTAL
Intervention: IgG CPS antibodies against serotypes Ia, II and III
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: IgM antibodies against serotype III CPS
Number of subjects: 321
Study: 8023538

Group type: EXPERIMENTAL
Intervention: Taprostene (T) at a continuous infusion of 25 ng/kg/min (in one case 12.5 ng/kg/min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2486180

Group type: EXPERIMENTAL
Intervention: Gentamicin serum levels determined only if renal dysfunction evident or if patient failed to respond to therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Gentamicin serum levels determined after the third dose
Number of subjects: 60
Study: 868906

Group type: EXPERIMENTAL
Intervention: Amikacin
Number of subjects: 53

Group type: COMPARATOR
Intervention: Gentamicin
Number of subjects: 53
Study: 30303859

Group type: EXPERIMENTAL
Intervention: EBUS-elastography
Number of subjects: 100

Group type: COMPARATOR
Intervention: EBUS
Number of subjects: 100
Study: 28875868

Group type: EXPERIMENTAL
Intervention: Dietary counselling as part of a multi-domain lifestyle intervention
Number of subjects: 1260

Group type: COMPARATOR
Intervention: Control group (no dietary counselling)
Number of subjects: 1260
Study: 25554551

Group type: EXPERIMENTAL
Intervention: Automated lateral rotation
Number of subjects: 15

Group type: COMPARATOR
Intervention: Manual lateral rotation
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 15
Study: 24074675

Group type: EXPERIMENTAL
Intervention: Packing Group (PG)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-Packing Group (NPG)
Number of subjects: 100
Study: 20826212

Group type: EXPERIMENTAL
Intervention: Bilateral on-stimulation
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Unilateral right-stimulation
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Unilateral left-stimulation
Number of subjects: 22

Group type: COMPARATOR
Intervention: Bilateral off-stimulation
Number of subjects: 22
Study: 19336730

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg twice daily
Number of subjects: 2035

Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg twice daily
Number of subjects: 2035

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2035
Study: 16771869

Group type: EXPERIMENTAL
Intervention: Tacrolimus + Mycophenolate Mofetil (FK group)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Cyclosporine A + Mycophenolate Mofetil (CsA group)
Number of subjects: 117
Study: 15090835

Group type: EXPERIMENTAL
Intervention: Higher maternal HIV-1 RNA level at or close to delivery
Number of subjects: 574
Study: 12193262

Group type: EXPERIMENTAL
Intervention: Straight‐line incisal access cavity
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lingual cingulum access cavity
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lingual conventional access cavity
Number of subjects: 30

Group type: COMPARATOR
Intervention: All access cavity types
Number of subjects: 30
Study: 9428939

Group type: EXPERIMENTAL
Intervention: Community intervention program including mass health education, nutrition education, antismoking propaganda, detection and treatment of hypertension, diabetes, and hyperlipidemia.
Number of subjects: 3585

Group type: COMPARATOR
Intervention: Control area with no intervention activities.
Number of subjects: 3585
Study: 8491161

Group type: EXPERIMENTAL
Intervention: Oily fish diet (170 g daily for 6 weeks)
Number of subjects: 18

Group type: COMPARATOR
Intervention: White fish diet (170 g daily for 6 weeks)
Number of subjects: 18
Study: 3326423

Group type: EXPERIMENTAL
Intervention: Droperidol (7.5 mg single dose)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Transdermal Scopolamine
Number of subjects: 40
Study: 29223745

Group type: EXPERIMENTAL
Intervention: Buparlisib (100 mg per day) plus fulvestrant (500 mg on days 1 and 15 of cycle 1 and on day 1 of subsequent 28-day cycles)
Number of subjects: 432

Group type: COMPARATOR
Intervention: Placebo plus fulvestrant (500 mg on days 1 and 15 of cycle 1 and on day 1 of subsequent 28-day cycles)
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Buparlisib
Number of subjects: 432

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 432
Study: 27611319

Group type: EXPERIMENTAL
Intervention: Couples counseling
Number of subjects: 1247

Group type: EXPERIMENTAL
Intervention: Women-only counseling
Number of subjects: 1247

Group type: COMPARATOR
Intervention: No counseling
Number of subjects: 1247
Study: 24860968

Group type: EXPERIMENTAL
Intervention: New and existing pharmacological strategies for constipation treatment
Number of subjects: 0
Study: 22666791

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nasal Dilator Strips
Number of subjects: 12
Study: 20466431

Group type: EXPERIMENTAL
Intervention: E‐EPA (1g/day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Both groups (E‐EPA and Placebo)
Number of subjects: 25
Study: 19038712

Group type: EXPERIMENTAL
Intervention: 24-hour pain pump with 0.375% ropivacaine infusion at a continuous rate of 5 mL/h
Number of subjects: 50

Group type: COMPARATOR
Intervention: No pain pump
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 24-hour pain pump with 0.375% ropivacaine infusion
Number of subjects: 50
Study: 16869138

Group type: EXPERIMENTAL
Intervention: Augmented feedback training program
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no feedback)
Number of subjects: 18
Study: 14569241

Group type: EXPERIMENTAL
Intervention: Extravascular lung density (ELD) measurement using SPECT imaging
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Post-exercise ELD measurement
Number of subjects: 13
Study: 10749259

Group type: EXPERIMENTAL
Intervention: MR imaging at 0.2 T
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: MR imaging at 1.5 T
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Inter-observer variability
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intra-observer variability
Number of subjects: 90
Study: 8843991

Group type: EXPERIMENTAL
Intervention: Oral riboflavin (20, 40, 60 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral riboflavin (40 mg) in female patients with liver cirrhosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous riboflavin (11.6 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral riboflavin (various doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Healthy females
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correction of peak concentrations and areas under the plasma curves
Number of subjects: 0
Study: 1536412

Group type: EXPERIMENTAL
Intervention: 4.5% albumin
Number of subjects: 2

Group type: COMPARATOR
Intervention: Synthetic colloid, polygeline
Number of subjects: 2
Study: 6486245

Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Number of subjects: 50
Study: 30772370

Group type: EXPERIMENTAL
Intervention: Warnings including health effects
Number of subjects: 1360

Group type: EXPERIMENTAL
Intervention: Warnings including nutrient disclosures
Number of subjects: 1360

Group type: EXPERIMENTAL
Intervention: Warnings with the marker word 'WARNING'
Number of subjects: 1360

Group type: EXPERIMENTAL
Intervention: Warnings with octagon shape
Number of subjects: 1360

Group type: COMPARATOR
Intervention: Warnings with health effects and nutrient disclosures
Number of subjects: 1360

Group type: EXPERIMENTAL
Intervention: Secondary outcomes (fear and thinking about harms)
Number of subjects: 1360
Study: 29579580

Group type: EXPERIMENTAL
Intervention: Exercise Stress Echocardiography (ESE)
Number of subjects: 385

Group type: COMPARATOR
Intervention: Exercise Electrocardiography (Ex‐ECG)
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Combined endpoint (death, myocardial infarction, unplanned revascularization, hospitalization for chest pain)
Number of subjects: 385
Study: 27296860

Group type: EXPERIMENTAL
Intervention: Progressive resistance exercise for 15 weeks, twice per week.
Number of subjects: 51

Group type: COMPARATOR
Intervention: Dynamic contractions (knee extension) performed during the study.
Number of subjects: 51
Study: 24841327

Group type: EXPERIMENTAL
Intervention: Risk prediction model for COPD based on routinely collected data
Number of subjects: 728658

Group type: EXPERIMENTAL
Intervention: Risk prediction model for COPD
Number of subjects: 728658
Study: 21821826

Group type: EXPERIMENTAL
Intervention: Acute intermittent hypoxia (AIH)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Sham exposure to room air
Number of subjects: 13
Study: 20160722

Group type: EXPERIMENTAL
Intervention: Current bisphosphonate users
Number of subjects: 5911

Group type: EXPERIMENTAL
Intervention: Increasing duration of bisphosphonate use
Number of subjects: 5911

Group type: EXPERIMENTAL
Intervention: Non-obese women
Number of subjects: 5911
Study: 19112384

Group type: EXPERIMENTAL
Intervention: CBT + 100mg trazodone
Number of subjects: 20

Group type: COMPARATOR
Intervention: CBT
Number of subjects: 20
Study: 15777362

Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Routine Clinical Care (RCC)
Number of subjects: 6
Study: 12223247

Group type: EXPERIMENTAL
Intervention: Problem-solving remediation techniques emphasizing intrinsic motivation, contextualization, personalization, and control of learning activities.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Problem-solving remediation techniques
Number of subjects: 0
Study: 11783223

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy combined with Chinese herbal medicine (CHM)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Thrombolytic therapy alone (Control)
Number of subjects: 101
Study: 9052030

Group type: EXPERIMENTAL
Intervention: 35 percent hydrogen peroxide bleaching system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Home bleaching system
Number of subjects: 0
Study: 2403697

Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 871187

Group type: EXPERIMENTAL
Intervention: Pancreatoduodenectomy
Number of subjects: 7